Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts have given Theravance Biopharma a consensus "Moderate Buy" rating from eight firms (four hold, two buy, two strong buy) with an average 12‑month price target of $21.83.
• Recent analyst activity is mixed: Zacks upgraded to strong-buy and several firms raised price targets (B. Riley to $17, TD Cowen to $15), while Weiss and Oppenheimer downgraded their ratings.
• SVP Rhonda Farnum sold 31,067 shares for about $433,695, reducing her stake, while the stock trades near $16.46 with a market cap of roughly $847.5M and high reported institutional ownership.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.8333.

TBPH has been the topic of several analyst reports. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Thursday, March 19th. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 7th. TD Cowen upped their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday, March 23rd. Weiss Ratings lowered shares of Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, April 10th. Finally, Oppenheimer downgraded shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a report on Thursday, March 5th.

Theravance Biopharma Trading Up 0.9%

NASDAQ TBPH opened at $16.46 on Friday. The firm's fifty day moving average price is $16.14 and its two-hundred day moving average price is $17.20. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The firm has a market capitalization of $847.53 million, a P/E ratio of 8.11 and a beta of 0.17.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of TBPH. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the first quarter valued at about $101,000. Jane Street Group LLC grew its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Creative Planning acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock valued at $1,009,000 after buying an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after buying an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.